Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EBC-129 |
Synonyms | |
Therapy Description |
EBC-129 is an antibody-drug conjugate (ADC) comprising an antibody targeting N-glycosylated CEACAM5/6 linked to monomethyl auristatin E (MMAE), which potentially induces antitumor activity (Ann Oncol 35 (2024): S516). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EBC-129 | EBC129|EBC 129 | CEACAM5 Antibody 8 CEACAM6 Antibody 3 | EBC-129 is an antibody-drug conjugate (ADC) comprising an antibody targeting N-glycosylated CEACAM5/6 linked to monomethyl auristatin E (MMAE), which potentially induces antitumor activity (Ann Oncol 35 (2024): S516). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05701527 | Phase I | EBC-129 + Pembrolizumab EBC-129 | A Study of EBC-129 in Advanced Solid Tumours | Recruiting | USA | 1 |